23 results about "Substantia nigra" patented technology

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The invention discloses a system for intelligently and automatically identifying and analyzing brain nigra high echo based on a transcranial ultrasonic image to assist in diagnosing Parkinson's disease, and relates to the technical field of image identification. Comprising an ultrasonic image data collection and preprocessing module, a deep learning model construction and training module, a nigra region accurate identification and segmentation module, a nigra region area measurement and statistical analysis module and a diagnosis result verification and visual output module. According to the method, an intelligent automatic identification model based on deep learning is constructed, and model optimization is carried out by using a large amount of manually labeled Parkinson's disease and health contrast ultrasonic image data, so that efficient identification segmentation and area measurement of a nigra region in a transcranial ultrasonic image are realized; and meanwhile, the performance of the model is comprehensively evaluated by using indexes of sensitivity, specificity and accuracy, so that the accuracy of an output result is ensured.

The invention belongs to the technical field of medicines, and discloses application of poliumoside to prevention and treatment of Parkinson's disease. Specifically, the invention discloses application of poliumoside as a compound shown in a formula (I) in the aspect of preventing and treating Parkinson's disease. Pharmacological experiments prove that after 14 days of administration of the poliumoside, the impairment of motor coordination function caused by MPTP-induced Parkinson's disease can be obviously improved, the reduction of the expression level of brain nigra tyrosine hydroxylase caused by MPTP is improved, and the result shows that the poliumoside has obvious pharmacological activity for preventing and treating Parkinson's disease. Therefore, poliumoside can be used for preparing the medicine for preventing and treating Parkinson's disease, and has high clinical application value and development prospect.

The invention discloses a tree shrew Parkinson's disease model making method which comprises the following specific steps: (1) Macrozam preparation: weighing required Macrozam under a sterile condition, and dissolving the Macrozam in sterilized ultrapure water to prepare a Macrozam working solution with the concentration of 10 mg / mL; (2) gavage: gavage is conducted on the tree shrew with Macrozamine using liquid, the dosage is 40-80 mg / kg according to the mass of the tree shrew body, and a stable tree shrew Parkinson's disease model is established after normal feeding is conducted for two weeks. According to the method, the tree shrew is subjected to intragastric administration with Macrozamine, the dosage is 40-80 mg / kg, and a stable tree shrew Parkinson's disease model can be established after two weeks. According to the scheme, three transformation medical bottlenecks of a traditional model are overcome for the first time through tree shrew nigra-striatum pathway anatomy conservative property, oral transformation advantage and dosage precise control three-dimensional innovation: (1) whole course simulation; (2) channel-level fidelity; and (3) high-value prediction. The model provides an irreplaceable standardized platform for Parkinson's disease mechanism research and clinical transformation.

The application discloses a device and method for detecting mouse motion learning behavior, and belongs to the field of animal behavior detection. The device comprises a mouse motion runway, a dark box at the terminal of the runway, and a camera for recording the motion process of the mouse. The runway is provided with a plurality of replaceable metal rods in the transverse direction. The metal rods are composed of any one or both of white metal rods and black metal rods. The runway composed of the black metal rods and the white metal rods is provided with any one of the metal rods for electrification, and the electrified metal rods are discontinuously arranged. The mouse is shocked by stepping on the electrified metal rods. The method of the application replaces the metal rods to form different runways, trains the mouse to reach the dark box through the different runways, and obtains the motion learning behavior ability of the mouse at different stages. The process of motion learning is simulated through programmed training. The role of the brain regions in the process of motion learning behavior is determined by regulating the regions of the substantia nigra or the striatum corresponding to the motion learning.

The application provides application of N-acyl dopamine family lipids in prevention and treatment of drug-induced Parkinson's disease motor complications, and belongs to the field of biological medicine. The application first proposes that the NADs compound can be used as a levodopa companion drug for preventing or treating levodopa-induced dyskinesia. The application takes 6-hydroxydopamine intracerebral injection and intraperitoneal injection of levodopa of an LID animal model as a research object, and studies the effect of NADs on improving LID. The results show that the NADs of the application can significantly improve the drug-induced PD motor complications LID, and it is proved that the NADs compound can be used as a companion drug to assist levodopa in treating PD.

The invention provides a traditional Chinese medicine composition for treating Parkinson's depression and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of radix acanthopanacis semticosi and 1-10 parts of bulbus lilii. The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: taking the acanthopanax and the lily, adding water to soak, heating, refluxing and extracting, and combining filtrate to obtain the traditional Chinese medicine composition. Animal experiments find that the acanthopanax-lily traditional Chinese medicine composition has a good treatment effect on Parkinson depression for the first time, and can remarkably improve dyskinesia and depression symptoms, regulate neurotransmitter disorder, relieve damage to nigra and hippocampal neurons and reduce the level of inflammatory factors in serum. After being taken for a long time, the traditional Chinese medicine composition disclosed by the invention can improve depression and life quality, slow down the progress of Parkinson disease and reduce the use of Parkinson drugs.

The application provides application of a hydroxy pentylbenzoic acid double ester compound L-NRB in treatment of Parkinson's disease. Animal model test proves that L-NRB can effectively improve the MPTP-induced Parkinson's disease mouse behavior index, increase the content of DA and its metabolites DOPAC and HVA in the brain, inhibit the loss of dopamine neurons in the substantia nigra and striatum, inhibit the expression of inflammatory factors and the activation of astrocytes and microglia in the substantia nigra; meanwhile, L-NRB can also inhibit the activity of MAO-B in the striatum. L-NRB has no toxic side effects in vivo and in vitro; has the advantages of high safety, small dosage, long-term stability and the like, and is suitable for further development for actual clinical treatment.

The invention belongs to the technical field of medicines, and particularly relates to application of a Chinese knotweed rhizome and aloe bowel-relaxing capsule to preparation of a medicine for treating Parkinson's disease. The Chinese knotweed rhizome and aloe bowel-relaxing capsule can obviously improve the damage of nigra and striatum dopaminergic neurons of mice suffering from the Parkinson's disease complicated with depression caused by MPTP and CUMS, and inhibit the activation of microglia and astroglia cells; the traditional Chinese medicine composition not only can relieve motion symptoms of mice with Parkinson's disease, but also can remarkably improve non-motion symptoms including mental disorder of the mice with Parkinson's disease, and has a remarkable treatment effect on depression of Parkinson's disease.

The present application relates to a kind of probiotic preparation for improving Parkinson's disease and its application, the strain in the probiotic preparation includes mucinophilic Akkermansia Akkermansia muciniphila Akk11 strain and Bifidobacterium breve Bifidobacterium breve BBr60 strain.The present application develops a brand-new probiotic compound mode and a brand-new probiotic intervention strategy for improving Parkinson's disease, i.e., Akk11 strain and BBr60 strain are compounded, it is found that there is potential interaction between the two, can cooperate with each other, synergistic effect in improving the efficacy of Parkinson's disease, specifically in: synergistically improving the motor disorders caused by Parkinson's disease, reducing the expression of related inflammatory factors in substantia nigra, promoting the generation of anti-inflammatory factors to relieve neurogenic inflammation, inhibiting the activation of inflammasome NLPR3 in substantia nigra to further inhibit brain inflammation.

The application relates to a magnetic resonance imaging image processing method, device, storage medium and electronic equipment, which comprises the following steps: performing spatial alignment and size normalization processing on an original three-dimensional MRI image to obtain a normalized MRI image; performing segmentation on the normalized MRI image to obtain a mask image set containing multiple regions of interest, wherein the regions of interest include a substantia nigra, a striatum and a globus pallidus; performing double-flow factorization coding on brain tissue data corresponding to the mask image set to obtain content features related to pathology and style features related to an imaging domain; performing reconstruction based on the content features and the style features to obtain a reconstructed image; performing double-flow factorization coding based on the reconstructed image, performing physical disturbance and adversarial alignment on the obtained double-flow coding, and obtaining disturbance features; and obtaining the classification corresponding to the original three-dimensional MRI image based on the disturbance features and a classification model obtained through pre-training. The classification accuracy can be improved.

The present invention discloses a method for establishing a clinically interpretable PD diagnostic model based on multi-sequence magnetic resonance brain features, which aims to promote a more accurate diagnosis of PD by extracting multi-level and multi-dimensional brain imaging information from multimodal brain magnetic resonance imaging data and constructing a diagnostic model with the help of machine learning. The method includes: brain imaging data preprocessing, feature standardization and screening, model construction, independent validation set and cross-disease set validation, and obtains a set of brain function and metabolic characteristics mainly based on PD abnormal perfusion patterns and substantia nigra iron distribution. The constructed model has high diagnostic efficacy in both the training set and the independent validation set. Secondly, the clinical interpretability of the model is promoted by calibration curve, DCA, CIC analysis, and correlation analysis between the predicted individual scores and clinical symptoms obtained based on the model. The diagnostic efficacy of the PD diagnostic model constructed by the present invention in different disease sets shows that the model has good diagnostic efficacy for PSP and MSA diseases.

The invention relates to a fluorescent probe for targeting lipid droplets with long-term retention capacity, a preparation method and application thereof, and belongs to the technical field of fluorescent probes. The structural formula of the fluorescent probe is shown in the specification. The ClogP value of the fluorescent probe is greater than 8, high-specificity targeting to lipid droplets can be realized, and the fluorescent probe can be stably retained in living cells for 72 hours. The fluorescent probe not only can trace abnormal accumulation of lipid droplets in a Parkinson's disease model on a cellular level, but also can realize visual detection of lipid droplet pathological accumulation in a nigra area of a living animal model through intracerebral in-situ injection. The fluorescent probe is obtained by carrying out a Knoevenagel reaction on 4, 4 '-diformyl triphenylamine and benzothiazole-2-acetonitrile, and has the characteristics of simplicity and convenience in synthesis, good biocompatibility, high signal-to-noise ratio and long cell retention time.

This invention relates to the field of pharmaceutical technology for treating motor dysfunction in Parkinson's disease, and particularly to a traditional Chinese medicine preparation for treating motor dysfunction in Parkinson's disease. The formula consists of Cimicifuga rhizome, processed turtle shell, Angelica sinensis, raw licorice root, ginger-processed Pinellia ternata, Gastrodia elata, and scorpion. This invention uses a traditional Chinese medicine formula to treat motor dysfunction in Parkinson's disease. The medicinal materials comply with national regulations for the management of traditional Chinese medicine materials and have undergone clinical testing. The formula is rationally formulated with high synergistic effects and long-lasting and stable efficacy. Based on the principles of traditional Chinese medicine syndrome differentiation and treatment, this formula addresses the deficiency of both liver and kidney, and the insufficiency of qi and blood, with tremor and paralysis attributed to internal liver wind. It significantly improves motor dysfunction and tremor symptoms in Parkinson's disease. This preparation is highly effective, safe, reliable, and has few side effects. It can also significantly reduce the expression levels of tyrosine hydroxylase in the substantia nigra and striatum. This preparation represents a new approach to treating motor dysfunction in Parkinson's disease and has broad prospects in the field of treating this condition.

The present application relates to a kind of Parkinson's disease animal model construction method, which is directly injected into the brain of animal by MPTP in the substantia nigra, and then the characteristic index score of animal is judged according to the characteristic index score standard, one Parkinson's disease animal model only needs to be injected once by MPTP for one animal, which is simple in operation process and short in time, greatly reduces the difficulty of modeling and animal care, which can achieve the purpose of modeling with a small amount of MPTP, thereby improving the modeling efficiency, and since the neurotoxicity response induced by MPTP is irreversible, MPTP is directly injected into the brain to act, which can also avoid the hindrance when MPTP is transmitted to the substantia nigra from other tissues of animal, thereby improving the success rate and stability of modeling.

The invention relates to the technical field of disease model construction, in particular to a construction method of a vascular Parkinson's syndrome composite animal model. The method comprises the following steps: sequentially performing chronic whole-brain hypoperfusion treatment and systemic mitochondrial complex I inhibition treatment on an advanced mammal, and applying the vascular Parkinson's syndrome animal model to preparation of a medicine for screening or evaluating prevention and / or treatment of the vascular Parkinson's syndrome. According to the construction method of the vascular Parkinson's syndrome composite animal model provided by the invention, a stable cerebrovascular lesion and a definite nigra-strike dopamine energy system are simultaneously induced on the same animal individual through an innovative double-strike modeling method; therefore, a brand-new animal model which is highly similar to human diseases in pathology is created.

The present invention belongs to the field of biomedicine, and in particular to the use of Lycium barbarum glycopeptide in the preparation of a medicament for preventing or treating drug-induced Parkinson's disease (PD) motor complications. Preferably, Lycium barbarum glycopeptide is used as a partner drug of levodopa to prevent or treat levodopa-induced dyskinesia. The present invention uses levodopa-induced dyskinesia (LID) animal models of 6-hydroxydopamine midbrain substantia nigra localized injection and levodopa intraperitoneal injection modeling as research objects, and studies the effect of Lycium barbarum glycopeptide in improving LID. The results showed that Lycium barbarum glycopeptide can significantly improve drug-induced PD motor complications LID, indicating that Lycium barbarum glycopeptide can be used as a partner drug to assist levodopa in treating PD.

The application discloses application of Dendrofin D in preparation of a medicine for preventing and / or treating Parkinson's disease, wherein the Parkinson's disease is caused by deficiency of a trace element, and the trace element is selenium; Dendrofin D can reduce MPP+-induced cell damage and damage of TH+ neurons in the substantia nigra, and can reduce motor disorders and non-motor disorders caused by Parkinson's disease; meanwhile, Dendrofin D and catalpol are combined to be applied in preparation of the medicine for preventing and / or treating Parkinson's disease, and the combination can effectively improve the protection on Parkinson's disease and related symptoms caused by the Parkinson's disease, has the effects of preventing and treating Parkinson's disease, and can improve motor disorders and non-motor disorders related to Parkinson's disease.

The invention relates to an application of a traditional Chinese medicine composition in preparation of a medicine for Parkinson's disease, which is characterized in that the traditional Chinese medicine composition is prepared from ginseng, rehmannia, cistanche, salvia miltiorrhiza, polygala tenuifolia, rhizoma acori graminei and curcuma aromatica. The composition provided by the invention can obviously improve mouse dyskinesia caused by a Parkinson's disease model, reduce level rise of IL-1beta, IL-18 and TNF-alpha caused by the mouse Parkinson's disease model, obviously increase the level of DA in nigra of brain tissues of rats with Parkinson's disease, and reduce the levels of IL-1beta and IL-6, and has a good treatment effect on Parkinson's disease.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of Shouhui Tongbian Capsules in the preparation of drugs for treating Parkinson's disease. Shouhui Tongbian Capsules can significantly improve the damage to dopamine neurons in the substantia nigra and striatum of Parkinson's disease mice with depression induced by MPTP and CUMS, and inhibit the activation of microglia and astrocytes; it not only alleviates the motor symptoms of Parkinson's disease mice, but also significantly improves the non-motor symptoms of Parkinson's disease mice, including mental disorders, and has a significant therapeutic effect on depression caused by Parkinson's disease.

The invention provides an application of miRNA-532-5p (micro Ribonucleic Acid-532-5p) in a Parkinson's disease treatment and prognosis target drug. In the invention, firstly, it is verified that after overexpression of miRNA-532-5p, the athletic ability of mice is obviously recovered, and the TH content of striatum and nigra is obviously increased compared with that of MPTP group mice; secondly, after the miRNA-532-5p is over-expressed, the mRNA level of an inflammatory factor is obviously reduced, and the mRNA level of an anti-inflammatory factor is obviously increased; and finally, after the miRNA-532-5p is over-expressed, the content of serum inflammatory factors is obviously reduced, and the content of anti-inflammatory factors is obviously increased. In conclusion, the miRNA-532-5p simulant can enhance the function of the miRNA-532-5p, so that the neuroinflammation is relieved, the condition of the Parkinson's disease is relieved, and a new strategy is provided for clinical treatment of the Parkinson's disease.

The application discloses a MAPKAPK2 molecule and application thereof to auxiliary diagnosis of Parkinson's disease. + The expression level of the MAPKAPK2 gene in peripheral blood, substantia nigra and prefrontal lobe of PD patients and healthy people is significantly different, and the MAPKAPK2 gene can be used as a potential molecular marker or target point of Parkinson's disease, applied to early clinical diagnosis and targeted treatment of Parkinson's disease, and is favorable for further elucidation of the occurrence and development mechanism and signal pathways of Parkinson's disease, and has great application prospect and theoretical value.

The invention provides a Parkinson's disease image automatic segmentation method based on improved TransUNet and Triplet Attention, which mainly solves the problem that a traditional Parkinson's disease nigra image is manually segmented by a doctor, and improves the Parkinson's disease diagnosis accuracy and the working efficiency of the doctor. According to the method, the improved TransUNet algorithm and a specially designed network structure are applied, so that the nigra area of the Parkinson's disease is effectively identified and segmented. Specifically, the model adopts dynamic up-sampling DySample, and the sampling mode is adaptively adjusted according to the characteristics of an input image. Meanwhile, a triple attention module is introduced into a decoding layer. The features of the nigra area are strengthened from the horizontal dimension, the vertical dimension and the channel dimension. The method provides an effective tool for Parkinson's disease medical image segmentation, and can meet the urgent requirements for high accuracy, high efficiency and high reliability in Parkinson's disease medical diagnosis and biomedical research.